Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors
"As uproleselan advances in late-stage clinical trials in acute myeloid leukemia (AML), Scott’s experience leading Celator through the successful development of Vyxeos® for treatment of newly diagnosed AML patients will be invaluable to GlycoMimetics,” said Rachel King, GlycoMimetics’ Chief Executive Officer. “His deep operational experience, including in sales, marketing and commercialization, is directly relevant as we look forward to potentially commercializing this novel drug candidate.”
Mr. Jackson has more than 25 years of experience in the pharmaceutical
and biotechnology industry and has held positions of increasing
responsibility in sales, marketing and commercial development at
“I am excited to join the GlycoMimetics Board at a time when the company is making tremendous strides in the development of glycomimetic compounds, such as uproleselan for AML,” said Mr. Jackson. “AML is an area of high unmet medical need and uproleselan, if approved, could potentially make a significant impact on the treatment of patients with AML. I look forward to working with the Board and leadership team to advance this important drug candidate and to leverage the potential of the company’s broad pipeline.”
About
GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including
statements regarding the clinical development and potential utility of
the company’s drug candidates. Actual results may differ materially from
those in these forward-looking statements. For a further description of
the risks associated with these statements, as well as other risks
facing
View source version on businesswire.com: https://www.businesswire.com/news/home/20181128005114/en/
Source:
Investor Contact:
Shari Annes
Phone: 650-888-0902
Email:
sannes@annesassociates.com
Media Contact:
Jamie Lacey-Moreira
Phone: 410-299-3310
Email:
jamielacey@presscommpr.com